Zoledronic acid for the prevention of bone metastases in patients with breast cancer

被引：0
|
作者：
Coleman, R. [1 ]
Gralow, J. [2 ]
Bell, R. [3 ]
Lipton, A. [4 ]
机构：
[1] Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
[2] Univ Washington, Sch Med Seattle Canc Care Alliance, Seattle, WA USA
[3] Andrew Love Canc Ctr, Geelong, Vic, Australia
[4] Milton S Hershey Med Ctr, Hershey, PA USA
来源：
EJC SUPPLEMENTS | 2004年 / 2卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(04)90666-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
63
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [11] A COMPARISON OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METASTASES
    Fujiwara, Yasuhiro
    Stopeck, Alison
    de Boer, Richard
    Lichinitser, Mikhail
    Tonkin, Katia
    Yardley, Denise
    Fan, Michelle
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Braun, Ada
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [12] Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
    Ito, Tokiko
    Ono, Mayu
    Oba, Takaaki
    Hanamura, Toru
    Kanai, Toshiharu
    Maeno, Kazuma
    Hiraguri, Manabu
    Shingu, Kiyoshi
    Kaneko, Gengo
    Ito, Ken-ichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [13] IMPAIRMENT OF RENAL FUNCTION IN THE BREAST CANCER PATIENTS WITH BONE METASTASES TREATED WITH ZOLEDRONIC ACID
    Ito, T.
    Shingu, K.
    Kaneko, G.
    Ito, K. -I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [14] A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases
    Stopeck, A.
    de Boer, R.
    Fujiwara, Y.
    Lichinitser, M.
    Tonkin, K.
    Yardley, D.
    Fan, M.
    Jiang, Q.
    Jun, S.
    Dansey, R.
    Braun, A.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 490S - 490S
  • [15] Zoledronic acid and atrial fibrillation in cancer patients with bone metastases
    Aksoy, S.
    Dizdar, O.
    Turgut, D.
    Dede, D. Sener
    Arslan, C.
    Harputluoglu, H.
    Altundag, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [16] Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    Chen, TL
    Berenson, J
    Vescio, R
    Swift, R
    Gilchick, A
    Goodin, S
    LoRusso, P
    Ma, PM
    Ravera, C
    Deckert, F
    Schran, H
    Seaman, J
    Skerjanec, A
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1228 - 1236
  • [17] Zoledronic acid in breast cancer patients with bone metastasis
    Halim, I. Abdel
    El Ashry, M.
    El Sherbini, E.
    El Sadda, W.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 279 - 280
  • [18] Zoledronic acid and survival in breast cancer patients with bone Metastases and elevated markers of osteoclast activity
    Lipton, Allan
    Cook, Richard J.
    Major, Pierre
    Smith, Matthew R.
    Coleman, Robert E.
    [J]. ONCOLOGIST, 2007, 12 (09): : 1035 - 1043
  • [19] Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases
    Lipton, A.
    Dewar, R.
    Conte, R.
    Zheng, M.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 142 - 142
  • [20] Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases
    Xie, Jipan
    Diener, Melissa
    Sorg, Rachael
    Wu, Eric Q.
    Namjoshi, Madhav
    [J]. CLINICAL BREAST CANCER, 2012, 12 (04) : 247 - 258
12345